| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA2407295
Max Phase: Preclinical
Molecular Formula: C25H38O3
Molecular Weight: 386.58
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H](OC(=O)c3cccc(O)c3)CCC[C@]12C
Standard InChI: InChI=1S/C25H38O3/c1-17(2)8-5-9-18(3)21-13-14-22-23(12-7-15-25(21,22)4)28-24(27)19-10-6-11-20(26)16-19/h6,10-11,16-18,21-23,26H,5,7-9,12-15H2,1-4H3/t18-,21-,22+,23+,25-/m1/s1
Standard InChI Key: YBURSFGXTMBMPR-BZTZPJLGSA-N
Associated Targets(Human)
Vitamin D receptor 26531 Activities
Smoothened homolog 1371 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Associated Targets(non-human)
Vitamin D receptor 250 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
C3H 10T1/2 488 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 386.58 | Molecular Weight (Monoisotopic): 386.2821 | AlogP: 6.60 | #Rotatable Bonds: 7 |
| Polar Surface Area: 46.53 | Molecular Species: NEUTRAL | HBA: 3 | HBD: 1 |
| #RO5 Violations: 1 | HBA (Lipinski): 3 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 1 |
| CX Acidic pKa: 9.14 | CX Basic pKa: | CX LogP: 7.49 | CX LogD: 7.48 |
| Aromatic Rings: 1 | Heavy Atoms: 28 | QED Weighted: 0.54 | Np Likeness Score: 1.64 |
References
| 1. DeBerardinis AM, Banerjee U, Hadden MK.. (2013) Identification of vitamin d3-based hedgehog pathway inhibitors that incorporate an aromatic a-ring isostere., 4 (7): [PMID:24900716] [10.1021/ml400014t] |
| 2. Deberardinis AM, Madden DJ, Banerjee U, Sail V, Raccuia DS, De Carlo D, Lemieux SM, Meares A, Hadden MK.. (2014) Structure-activity relationships for vitamin D3-based aromatic a-ring analogues as hedgehog pathway inhibitors., 57 (9): [PMID:24730984] [10.1021/jm401812d] |
| 3. DeBerardinis AM, Raccuia DS, Thompson EN, Maschinot CA, Kyle Hadden M.. (2015) Vitamin D3 analogues that contain modified A- and seco-B-rings as hedgehog pathway inhibitors., 93 [PMID:25676864] [10.1016/j.ejmech.2015.01.049] |
| 4. Maschinot CA, Chau LQ, Wechsler-Reya RJ, Hadden MK.. (2019) Synthesis and evaluation of third generation vitamin D3 analogues as inhibitors of Hedgehog signaling., 162 [PMID:30471551] [10.1016/j.ejmech.2018.11.028] |
Source
Source(1):